Drug Trial Radar · NCT07915219
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jan 11, 2027
Primary completion
Jul 31, 2029
Study completion Sep 10, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes. This is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017). All participants receive verducatib. Participants take verducatib as tablets once a day at home. They may continue their usual treatment for bronchiectasis during the study. Participants can stay in the study for up to 1 year and 9 months. Treatment with verducatib can continue for up to 1 year and 6 months. About 6 study visits are done at the study site and about 4 are done by phone. At all visits, the doctors check participants' health and collect information on any health problems that occur during the study. The doctors also look at lung flare-ups and measure lung function over time.
Conditions
- Bronchiectasis
Interventions
verducatibDrug
verducatib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trialTime frame: up to 78 weeks
Locations
394 sites in 41 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Arizona
Tucson, Arizona
Newport Native MD, Inc
Newport Beach, California
Paradigm Clinical Research - Redding
Redding, California
University of California Davis
Sacramento, California
University of California San Francisco
San Francisco, California
National Jewish Health
Denver, Colorado
Meris Clinical Research-Brandon-69466
Brandon, Florida
University of Florida College of Medicine
Jacksonville, Florida
Mayo Clinic - Florida
Jacksonville, Florida
Essence MD Research
Naples, Florida
Vantage Clinical Trials - Tampa
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Augusta University
Augusta, Georgia
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
HealthPartners Specialty Center 401 Building
Saint Paul, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
New York Medical College - Hawthorne
Hawthorne, New York
Northwell Health
New Hyde Park, New York
New York University Langone Medical Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
New York Presbyterian Hospital -Columbia University
New York, New York
Stern Research Partners, LLC
Huntersville, North Carolina
Pinehurst Medical Clinic, Inc. - East
Pinehurst, North Carolina
University of Cincinnati
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Clinical Research Associates of Central PA
DuBois, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Jefferson Health Honickman Center
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Clinical Research of Rock Hill
Rock Hill, South Carolina
Horizon Clinical Research Group
Cypress, Texas
Baylor University Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
El Paso Pulmonary Association
El Paso, Texas
University of Texas Medical Branch at Galveston
Galveston, Texas
Showing 40 of 394 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.